North Chicago, Illinois-based AbbVie Inc. (ABBV) discovers, develops, manufactures, and sells pharmaceuticals worldwide. With ...

Drugmakers are turning to biomarkers, like folate receptor alpha, and even cell therapies to tackle this deadly cancer in new ...

Toon Van Gorp, MD, PhD, discusses the rationale behind and the findings from the phase 3 MIRASOL trial of mirvetuximab ...

AbbVie is sprinting beyond its Humira dependency by banking on rising stars Skyrizi and Rinvoq, which are smashing sales ...

Genmab has shared the first data on rinatabart sesutecan (Rina-S) in advanced endome | Genmab has shared the first data on ...

Results of the trial, which evaluated the efficacy and safety of mirvetuximab soravtansine-gynx (Elahere, AbbVie), were presented at Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.

The ImmunoGen deal's star is the ovarian cancer drug Elahere, which had sales of $479 million in 2024. AbbVie is in the process of expanding its use cases significantly to boost sales. Unfortunately, ...

Elahere (mirvetuximab soravtansine-gynx) is a brand-name injection that’s prescribed for certain types of cancer. Elahere has interactions with some other drugs. Examples include certain ...

AbbVie’s Elahere (mirvetuximab soravtansine-gynx) has demonstrated consistent survival benefits in a subset of ovarian cancer patients, according to results from a confirmatory late-stage trial of the ...

Elahere showed superior efficacy over chemotherapy in progression-free survival, objective response rate, and overall survival in the MIRASOL trial. The treatment reduced the risk of tumor progression ...

Final data analysis from Phase 3 MIRASOL trial after 30.5-month median follow-up demonstrated 32% reduction in risk of death with ELAHERE compared to chemotherapy in folate receptor alpha (FRα ...